Risk of thyroid cancer related to glucagon-like peptide-1 receptor agonists: A systematic review with meta-analysis of harms of randomized controlled trials.

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2025-06-05 DOI:10.1111/dom.16504

Lucas Duchemin, Arthur Morice, Pierre-Marie Morice, Claire Bernardeau, Joachim Alexandre, Sophie Fedrizzi, Angélique Da Silva, Louis Boismoreau, Jean-Luc Faillie, Charles Dolladille

引用次数: 0

查看原文本刊更多论文

胰高血糖素样肽-1受体激动剂与甲状腺癌风险相关：随机对照试验危害荟萃分析的系统综述

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.